Newish Technology (Beijing) Co., Ltd.
11
4
4
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
9.1%
1 terminated/withdrawn out of 11 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
100%
1 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
NWRD06 DNA Plasmid for HCC After Curative Resection.
Role: lead
NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer
Role: lead
NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.
Role: lead
NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL
Role: lead
NWRD06 DNA Plasmid for HCC After Radical Resection
Role: lead
NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
Role: lead
Clinical Study of HPV Therapeutic DNA Vaccine (NWRD08) in Patients With Cervical HPV16 and/or HPV18 Positive
Role: lead
Clinical Trial of Autologous Tcm Immunotherapy in ICC
Role: lead
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
Role: collaborator
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
Role: collaborator
Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
Role: collaborator
All 11 trials loaded